1. Home
  2. FOLD vs EXG Comparison

FOLD vs EXG Comparison

Compare FOLD & EXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FOLD
  • EXG
  • Stock Information
  • Founded
  • FOLD 2002
  • EXG 2007
  • Country
  • FOLD United States
  • EXG United States
  • Employees
  • FOLD N/A
  • EXG N/A
  • Industry
  • FOLD Biotechnology: Pharmaceutical Preparations
  • EXG Finance Companies
  • Sector
  • FOLD Health Care
  • EXG Finance
  • Exchange
  • FOLD Nasdaq
  • EXG Nasdaq
  • Market Cap
  • FOLD 2.8B
  • EXG 2.5B
  • IPO Year
  • FOLD 2007
  • EXG N/A
  • Fundamental
  • Price
  • FOLD $9.50
  • EXG $8.38
  • Analyst Decision
  • FOLD Strong Buy
  • EXG
  • Analyst Count
  • FOLD 8
  • EXG 0
  • Target Price
  • FOLD $17.57
  • EXG N/A
  • AVG Volume (30 Days)
  • FOLD 2.4M
  • EXG 533.2K
  • Earning Date
  • FOLD 11-06-2024
  • EXG 01-01-0001
  • Dividend Yield
  • FOLD N/A
  • EXG 8.27%
  • EPS Growth
  • FOLD N/A
  • EXG N/A
  • EPS
  • FOLD N/A
  • EXG N/A
  • Revenue
  • FOLD $493,671,000.00
  • EXG N/A
  • Revenue This Year
  • FOLD $33.97
  • EXG N/A
  • Revenue Next Year
  • FOLD $21.74
  • EXG N/A
  • P/E Ratio
  • FOLD N/A
  • EXG N/A
  • Revenue Growth
  • FOLD 32.58
  • EXG N/A
  • 52 Week Low
  • FOLD $9.02
  • EXG $6.78
  • 52 Week High
  • FOLD $14.57
  • EXG $8.15
  • Technical
  • Relative Strength Index (RSI)
  • FOLD 28.33
  • EXG 43.69
  • Support Level
  • FOLD $9.37
  • EXG $8.31
  • Resistance Level
  • FOLD $9.68
  • EXG $8.51
  • Average True Range (ATR)
  • FOLD 0.49
  • EXG 0.12
  • MACD
  • FOLD -0.18
  • EXG -0.01
  • Stochastic Oscillator
  • FOLD 3.96
  • EXG 18.06

About FOLD Amicus Therapeutics Inc.

Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases.

About EXG Eaton Vance Tax-Managed Global Diversified Equity Income Fund of Beneficial Interest

Eaton Vance Tax-Mgd Glbl Div Eq Inc is a diversified, closed-end management investment company. Its primary investment objective is to provide current income and gains. The secondary objective of the fund is capital appreciation. It invests in a diversified portfolio of domestic and foreign common stocks with an emphasis on dividend-paying stocks and writes call options on one or more U.S. and foreign indices with respect to a portion of the value of its common stock portfolio to generate current cash flow from the options premium received. Its portfolio of investments consists of capital markets, banks, internet and direct marketing retail, biotechnology, media, oil, gas, and consumable fuels, and other sectors.

Share on Social Networks: